[go: up one dir, main page]

TR200102338T2 - Siklik ikame edilmiş bağlı pirolokarbazoller ve izoindolonlar. - Google Patents

Siklik ikame edilmiş bağlı pirolokarbazoller ve izoindolonlar.

Info

Publication number
TR200102338T2
TR200102338T2 TR2001/02338T TR200102338T TR200102338T2 TR 200102338 T2 TR200102338 T2 TR 200102338T2 TR 2001/02338 T TR2001/02338 T TR 2001/02338T TR 200102338 T TR200102338 T TR 200102338T TR 200102338 T2 TR200102338 T2 TR 200102338T2
Authority
TR
Turkey
Prior art keywords
pyrolocarbazoles
isoindolones
cyclic substituted
substituted linked
linked
Prior art date
Application number
TR2001/02338T
Other languages
English (en)
Inventor
L. Hudkins Robert
Reddy Dandu
Singh Jasbir
Tripathy Rabindranath
Underiner Theodore
Original Assignee
Cephalon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon, Inc. filed Critical Cephalon, Inc.
Publication of TR200102338T2 publication Critical patent/TR200102338T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)

Abstract

Mevcut bulus, formül I'e sahip siklik ikame edilmis bagli pirolokarbazoller ve izoindolonlar ile ilgilidir. Bulus, siklik ikame edilmis bagli pirolokarbazollerin ve izoindolonlarin hazirlanmasina ve kullanilmasina yönelik metotlarla da ilgilidir. Bilesikler, protein kinaz düzenleyici maddeler olarak faydalidir.
TR2001/02338T 1999-02-12 2000-02-11 Siklik ikame edilmiş bağlı pirolokarbazoller ve izoindolonlar. TR200102338T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11983499P 1999-02-12 1999-02-12
US09/500,849 US6841567B1 (en) 1999-02-12 2000-02-10 Cyclic substituted fused pyrrolocarbazoles and isoindolones

Publications (1)

Publication Number Publication Date
TR200102338T2 true TR200102338T2 (tr) 2002-07-22

Family

ID=26817753

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02338T TR200102338T2 (tr) 1999-02-12 2000-02-11 Siklik ikame edilmiş bağlı pirolokarbazoller ve izoindolonlar.

Country Status (18)

Country Link
US (3) US6841567B1 (tr)
EP (1) EP1165562A1 (tr)
JP (1) JP2003529537A (tr)
KR (1) KR100697732B1 (tr)
CN (1) CN1350537A (tr)
AU (1) AU773335B2 (tr)
BR (1) BR0008056A (tr)
CA (1) CA2359772C (tr)
CZ (1) CZ20012878A3 (tr)
EA (1) EA005273B1 (tr)
HR (1) HRP20010583A2 (tr)
IS (1) IS6015A (tr)
NO (1) NO322210B1 (tr)
NZ (1) NZ513097A (tr)
PL (1) PL352530A1 (tr)
SK (1) SK11292001A3 (tr)
TR (1) TR200102338T2 (tr)
WO (1) WO2000047583A1 (tr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
WO2002014536A2 (en) * 2000-08-11 2002-02-21 Cephalon, Inc. Odulating multiple lineage kinase proteins
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
DE10164581A1 (de) * 2001-12-14 2003-06-26 Gruenenthal Gmbh Substituierte Aminoalkohole
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PT1656372E (pt) 2003-07-30 2013-06-27 Rigel Pharmaceuticals Inc Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
DE102004025726B4 (de) * 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
NZ563454A (en) 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
EP2124554B1 (en) * 2006-12-14 2012-02-08 Tautatis, Inc. Compositions and methods for the treatment of cancer
US20100173426A1 (en) * 2006-12-19 2010-07-08 Johnson Faye M Biomaker identifying the reactivation of stat3 after src inhibition
US9061009B2 (en) * 2007-06-08 2015-06-23 University Of Massachusetts Mixed lineage kinases and metabolic disorders
WO2009103032A1 (en) 2008-02-15 2009-08-20 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
US20110092452A1 (en) * 2008-03-05 2011-04-21 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
AU2009244897B2 (en) 2008-04-16 2014-11-13 Alexion Pharmaceuticals, Inc. 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
AU2009238590A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2010059795A1 (en) 2008-11-19 2010-05-27 Cephalon, Inc. Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound
WO2011017178A1 (en) * 2009-07-28 2011-02-10 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
KR20120082906A (ko) 2009-09-30 2012-07-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법
TW201300360A (zh) 2010-11-01 2013-01-01 Portola Pharm Inc 做為ｊａｋ激酶調節劑之菸鹼醯胺
EA201391486A1 (ru) * 2011-04-07 2014-09-30 Ариад Фармасьютикалз, Инк. Способы и композиции для лечения болезни паркинсона
AU2012340555B2 (en) 2011-11-23 2016-10-20 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
CA3131037A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
WO2014145485A2 (en) 2013-03-15 2014-09-18 The Trustees Of Columbia University In The City Of New York Map kinase modulators and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US473939A (en) * 1892-05-03 mason
JPS62220196A (ja) 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
WO1988007045A1 (en) 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
FR2631199B1 (fr) 1988-05-09 1991-03-15 Centre Nat Rech Scient Reacteur a plasma
US5621101A (en) 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
EP0839814A3 (en) 1993-05-28 1998-09-16 Cephalon, Inc. Indolocarbazole derivatives and their use for the treatment of prostate gland disorders
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
ATE456367T1 (de) 1993-12-23 2010-02-15 Lilly Co Eli Proteinkinase c inhibitoren
US5594009A (en) 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5591855A (en) 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
AU6888196A (en) 1995-08-11 1997-03-12 Yale University Glycosylated indolocarbazole synthesis
TW403754B (en) 1995-11-20 2000-09-01 Lilly Co Eli Protein kinase c inhibitor
US5808060A (en) 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
US5616724A (en) 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
WO1998007433A1 (en) 1996-08-22 1998-02-26 Bristol-Myers Squibb Company Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles
WO1999047522A1 (en) 1998-03-13 1999-09-23 The University Of British Columbia Granulatimide derivatives for use in cancer treatment
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
EP1105728B1 (en) 1998-08-26 2005-04-13 Cephalon, Inc. Modulating multiple lineage kinase proteins
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones

Also Published As

Publication number Publication date
IS6015A (is) 2001-07-20
EP1165562A1 (en) 2002-01-02
SK11292001A3 (sk) 2002-04-04
CN1350537A (zh) 2002-05-22
US7288650B2 (en) 2007-10-30
US20060128780A1 (en) 2006-06-15
WO2000047583A8 (en) 2001-03-29
KR100697732B1 (ko) 2007-03-22
AU773335B2 (en) 2004-05-20
EA005273B1 (ru) 2004-12-30
PL352530A1 (en) 2003-08-25
KR20010102085A (ko) 2001-11-15
WO2000047583A9 (en) 2001-09-20
CZ20012878A3 (cs) 2002-08-14
NO322210B1 (no) 2006-08-28
WO2000047583A1 (en) 2000-08-17
US6841567B1 (en) 2005-01-11
BR0008056A (pt) 2002-04-09
EA200100887A1 (ru) 2002-02-28
NZ513097A (en) 2004-05-28
US20040186157A1 (en) 2004-09-23
NO20013887D0 (no) 2001-08-09
US7074793B2 (en) 2006-07-11
JP2003529537A (ja) 2003-10-07
NO20013887L (no) 2001-10-11
HRP20010583A2 (en) 2002-08-31
CA2359772C (en) 2009-08-11
AU3360400A (en) 2000-08-29
CA2359772A1 (en) 2000-08-17

Similar Documents

Publication Publication Date Title
TR200102338T2 (tr) Siklik ikame edilmiş bağlı pirolokarbazoller ve izoindolonlar.
DE60236600D1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
TR200101499T1 (tr) Azepinoindol türevleri, hazırlanmaları ve kullanımları.
DK1200418T3 (da) Nematodicide trifluorbutener
ID27124A (id) Penghambat kinase bisiklik
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
EA200400815A1 (ru) Контролируемый синтез зипразидона и его композиции
ATE290529T1 (de) Biphenylderivate, ihre herstellung und ihre verwendung als mtp-inhibitor
BG100069A (bg) Амидинови производни,съдържащи хетероциклични групи,получаване и приложението им
ATE297903T1 (de) Substituierte phenyluracile
TR200002932T2 (tr) Azabisayklik 5HT1 Alıcı liganolları
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
DE60139770D1 (de) Hydantoin derivate mit affinität für somatostatin rezeptoren
MXPA03008248A (es) Agentes colorantes para fibras de queratina que contienen derivados de n-heteroarilmetil-m-fenilendiamina, asi como nuevos derivados de n-heteroarilmetil-m-fenilendiamina.
SE9904128D0 (sv) Novel compounds
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri
DK1178985T3 (da) Substituerede thienocycloalk(en)ylamino-1,3,5-triaziner
ATE213236T1 (de) Substituierte benzyloxyimino-verbindungen
EA199800368A1 (ru) Новые промежуточные продукты и их использование для получения n,n'-мостиковых бисиндолилмалеимидов
PT1104419E (pt) Derivados de azabicicloheptano substituidos no azoto sua preparacao e utilizacao
ATE247649T1 (de) Disubstituierte biphenyloxazoline
DK1051404T3 (da) Substituerede phenyluraciler med herbicid virkning
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine
DK0713485T3 (da) Thiocarbamoylforbindelser som mikrobicider
ATE261962T1 (de) Benzonaphtyridin-1,8 derivate